Healthcare provider profile · identity verified

Atilio Abreu Serrano, MD

Family Practice · BAYTOWN, TX · NPI 1407087323

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	344	115
Metformin Hcl	Metformin Hcl	282	98
Lisinopril	Lisinopril	252	84
Losartan Potassium	Losartan Potassium	246	85
Amlodipine Besylate	Amlodipine Besylate	234	81
Rosuvastatin Calcium	Rosuvastatin Calcium	227	90
Pantoprazole Sodium	Pantoprazole Sodium	185	79
Levothyroxine Sodium	Levothyroxine Sodium	158	48
Tizanidine Hcl	Tizanidine Hcl	158	81
Fluticasone Propionate	Fluticasone Propionate	149	75
Metoprolol Succinate	Metoprolol Succinate	144	53
Gabapentin	Gabapentin	133	56
Simvastatin	Simvastatin	125	39
Jardiance	Empagliflozin	118	37
Glipizide	Glipizide	105	35
Omeprazole	Omeprazole	101	33
Albuterol Sulfate Hfa	Albuterol Sulfate	93	41
Ezetimibe	Ezetimibe	90	30
Hydrochlorothiazide	Hydrochlorothiazide	90	31
Furosemide	Furosemide	82	41
Tamsulosin Hcl	Tamsulosin Hcl	78	35
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	75	26
Allopurinol	Allopurinol	74	24
Famotidine	Famotidine	71	32
Pioglitazone Hcl	Pioglitazone Hcl	69	22
Metoprolol Tartrate	Metoprolol Tartrate	68	28
Clopidogrel	Clopidogrel Bisulfate	66	27
Alendronate Sodium	Alendronate Sodium	65	23
Hydralazine Hcl	Hydralazine Hcl	63	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	63	20
Meloxicam	Meloxicam	62	29
Ozempic	Semaglutide	62	19
Diclofenac Sodium	Diclofenac Sodium	61	40
Escitalopram Oxalate	Escitalopram Oxalate	56	22
Trazodone Hcl	Trazodone Hcl	56	19
Alprazolam	Alprazolam	54	14
Azithromycin	Azithromycin	52	44
Farxiga	Dapagliflozin Propanediol	52	17
Pregabalin	Pregabalin	52	13
Montelukast Sodium	Montelukast Sodium	49	15
Eliquis	Apixaban	47	18
Triamcinolone Acetonide	Triamcinolone Acetonide	43	28
Donepezil Hcl	Donepezil Hcl	42	19
Duloxetine Hcl	Duloxetine Hcl	42	15
Carvedilol	Carvedilol	38	14
Potassium Chloride	Potassium Chloride	37	14
Tramadol Hcl	Tramadol Hcl	35	14
Zolpidem Tartrate	Zolpidem Tartrate	35	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	33	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	33	26
Valsartan	Valsartan	33	14
Celecoxib	Celecoxib	32	12
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	31	20
Dicyclomine Hcl	Dicyclomine Hcl	31	19
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	31	15
Prednisone	Prednisone	30	26
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	13
Meclizine Hcl	Meclizine Hcl	28	18
Naproxen	Naproxen	28	17
Atenolol	Atenolol	27	suppressed
Metformin Hcl Er	Metformin Hcl	27	suppressed
Glimepiride	Glimepiride	26	suppressed
Nifedipine Er	Nifedipine	26	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	25	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Clonidine Hcl	Clonidine Hcl	24	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Sertraline Hcl	Sertraline Hcl	24	suppressed
Ibuprofen	Ibuprofen	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Lactulose	Lactulose	23	14
Latanoprost	Latanoprost	23	suppressed
Methylprednisolone	Methylprednisolone	23	20
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Mounjaro	Tirzepatide	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Finasteride	Finasteride	18	suppressed
Ondansetron Odt	Ondansetron	18	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Trulicity	Dulaglutide	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Levemir Flexpen	Insulin Detemir	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Doxepin Hcl	Doxepin Hcl	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Linzess	Linaclotide	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Colchicine	Colchicine	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Topiramate	Topiramate	14	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	12
Sucralfate	Sucralfate	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Cevimeline Hcl	Cevimeline Hcl	12	suppressed
Glyburide-Metformin Hcl	Glyburide/Metformin Hcl	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	11	suppressed
Aripiprazole	Aripiprazole	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Levemir	Insulin Detemir	11	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	11	11
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error